Encainide: Difference between revisions
(Created page with "==Administration== *Type: Class IC antiarrhythmic (sodium channel blocker) *Dosage Forms: Capsules (25mg or 35mg) *Routes of Administration: PO *Common Trade Names: Enkaid ==...") |
No edit summary |
||
| (10 intermediate revisions by one other user not shown) | |||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Sustained | ===Sustained [[ventricular tachycardia]]=== | ||
* 25mg PO t.i.d | * 25mg PO t.i.d | ||
**May be increased to 35mg PO t.i.d after 3-5 days | **May be increased to 35mg PO t.i.d after 3-5 days | ||
| Line 15: | Line 15: | ||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *Category B | ||
===Lactation risk=== | ===Lactation risk=== | ||
* | *Unknown risk to nursing infants | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed. | ||
*Pediatric: | *Pediatric: N/A | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: | *Adult: No adjustments needed, but use caution when increasing dosage | ||
*Pediatric: | *Pediatric: N/A | ||
==Contraindications== | ==Contraindications== | ||
| Line 36: | Line 36: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*Provocation or aggravation of ventricular arrhythmias | |||
*2nd or 3rd-degree AV block | |||
*Sinus bradycardia | |||
===Common=== | ===Common=== | ||
* Dizziness | |||
* Blurred/abnormal vision | |||
* Headache | |||
==Pharmacology== | |||
==Pharmacology== | *Half-life: Genetically determined; 1-2 hours for 90% of patients; 6-11 hours for 10% of patients<ref>Gruetter, C., 2016. Encainide - an overview | ScienceDirect Topics. [online] Sciencedirect.com. Available at: <https://www.sciencedirect.com/topics/medicine-and-dentistry/encainide> [Accessed 27 June 2021].</ref> | ||
*Half-life: | *Metabolism: Hepatic; Encainide converts to two active metabolites (ODE and MODE) | ||
*Metabolism: | *Excretion: Urine and feces | ||
*Excretion: | *Mechanism of action: Blocks sodium channels in purkinje fibers and myocardium; slows conduction, reduces membrane responsiveness, and inhibits automaticity<ref>Drugs.com. 2021. Enkaid - FDA prescribing information, side effects and uses. [online] Available at: <https://www.drugs.com/pro/enkaid.html#s-34067-9> [Accessed 27 June 2021].</ref> | ||
==Comments== | ==Comments== | ||
Latest revision as of 12:30, 24 July 2021
Administration
- Type: Class IC antiarrhythmic (sodium channel blocker)
- Dosage Forms: Capsules (25mg or 35mg)
- Routes of Administration: PO
- Common Trade Names: Enkaid
Adult Dosing
Sustained ventricular tachycardia
- 25mg PO t.i.d
- May be increased to 35mg PO t.i.d after 3-5 days
Pediatric Dosing
- Safety and effectiveness in pediatrics not established
Special Populations
Pregnancy Rating
- Category B
Lactation risk
- Unknown risk to nursing infants
Renal Dosing
- Adult: Reduce to single initial daily 25mg dose; increase to 25mg b.i.d after 7 days if needed.
- Pediatric: N/A
Hepatic Dosing
- Adult: No adjustments needed, but use caution when increasing dosage
- Pediatric: N/A
Contraindications
- Allergy to class/drug
- Preexisting 2nd or 3rd-degree AV block
- Preexisting right bundle branch block w/ left hemiblock
- Presence of cardiogenic shock
Adverse Reactions
Serious
- Provocation or aggravation of ventricular arrhythmias
- 2nd or 3rd-degree AV block
- Sinus bradycardia
Common
- Dizziness
- Blurred/abnormal vision
- Headache
Pharmacology
- Half-life: Genetically determined; 1-2 hours for 90% of patients; 6-11 hours for 10% of patients[1]
- Metabolism: Hepatic; Encainide converts to two active metabolites (ODE and MODE)
- Excretion: Urine and feces
- Mechanism of action: Blocks sodium channels in purkinje fibers and myocardium; slows conduction, reduces membrane responsiveness, and inhibits automaticity[2]
Comments
See Also
References
- ↑ Gruetter, C., 2016. Encainide - an overview | ScienceDirect Topics. [online] Sciencedirect.com. Available at: <https://www.sciencedirect.com/topics/medicine-and-dentistry/encainide> [Accessed 27 June 2021].
- ↑ Drugs.com. 2021. Enkaid - FDA prescribing information, side effects and uses. [online] Available at: <https://www.drugs.com/pro/enkaid.html#s-34067-9> [Accessed 27 June 2021].